key: cord-252306-68eogdyc
authors: Adler, Hugh; Ball, Robert; Fisher, Michael; Mortimer, Kalani; Vardhan, Madhur S
title: Low rate of bacterial co-infection in patients with COVID-19
date: 2020-06-30
journal: The Lancet Microbe
DOI: 10.1016/s2666-5247(20)30036-7
sha: 
doc_id: 252306
cord_uid: 68eogdyc

nan

We reviewed all microbiology results for patients admitted to Whiston hospital (Prescot, UK) with PCR-confirmed COVID-19 between March 6, 2020, and April 7, 2020. Hospital policy for patients admitted with community-acquired pneumonia, including suspected COVID-19 cases, recommends blood cultures and pneumococcal and Legionella urinary antigen tests based on clinical severity, in line with national guidelines. 7 We collected the data to inform and update the hospital's antimicrobial policy, with approval from the Trust Quality Improvement and Clinical Audit department. We recorded results for 7 days from the positive COVID-19 test because positive samples collected after this time period might represent hospital-acquired infections. Samples unequivocally consistent with contamination were considered negative.

We identified 195 patients (for demographics and microbiology see appendix p 1). Five (3% of 195, or 4% of 137 patients specifically tested), had pneumococcal co-infection and all survived to hospital discharge. One of 31 patients tested was positive for the Legionella antigen without lower respiratory tract samples to confirm legionellosis. Bacteria grew from four of 26 sputum samples (appendix p 1). All bacteria were Gram-negative bacilli more typically associated with oropharyngeal colonisation than community-acquired pneumonia.

Our findings suggest that bacterial co-infection is uncommon in patients with COVID-19 who are newly admitted to hospital. The coprevalence of pneumococcus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was low, and Staphylococcus aureus was not detected. By contrast, in influenza infection the prevalence of bacterial coinfection in hospitalised patients can exceed 30%. 8, 9 These results suggest that routine antibiotics might not be indicated in patients with COVID-19. If superimposed bacterial communityacquired pneumonia is suspected, coverage for typical pathogens such as pneumococcus might suffice, unless there is specific clinical concern for infection with atypical agents.

The main strength of our report is the correlation of microbiology results with all consecutive COVID-19 admissions. The main limitation is the variability of microbiological sampling. Our results might not be generalisable to other geographical settings.

Future studies should implement standardised microbiological sampling for all COVID-19 admissions and prospectively correlate the prevalence of co-infection with mortality rates. Such studies could also correlate clinical and laboratory findings with the presence of co-infection to support rational prescribing of antibiotics.

Pantonvalentine leukocidin-secreting Staphylococcus aureus pneumonia complicating COVID-19

First COVID-19 infections in the Philippines: a case report

Case report: the importance of novel coronavirus disease (COVID-19) and coinfection with other respiratory pathogens in the current pandemic

Clinical management of persons admitted to hospital with suspected COVID-19 infection

clinical-management-ofsevere-acute-respiratory-infection-whennovel-coronavirus-(ncov)-infection-issuspected

BTS guidelines for the management of community acquired pneumonia in adults: update

Bacterial coinfection in influenza: a grand rounds review

Pneumonia and Hong Kong influenza: a prospective study of the 1968-69 epidemic